Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for the majority of patients with high-risk or advanced hematologic malignancies. Schöttker et al. describe the case of a male patient with acute lymphoblastic leukemia who received cord-blood, third-party CD34+stem-cell, and T-cell transplantation after experiencing primary graft failure. The authors discuss the therapeutic potential of this combined non-HLA restricted transplantation for patients with hematologic disorders.
- Björn Schöttker
- Tobias Feuchtinger
- Gernot Stuhler